Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenues	$ 226	$ 96	$ 581	$ 271
Cost of revenues	18	10	43	31
Gross profit	208	86	538	240
Operating expenses
Selling, general and administrative	2,953	2,882	9,319	8,251
Research and development	276	63	534	181
Acquired in-process research and development	0	0	1,967	0
Total operating expenses	3,229	2,945	11,820	8,432
Operating loss	(3,021)	(2,859)	(11,282)	(8,192)
Other income (expenses), net
Interest income	10	7	31	47
Change in fair value of royalties payable due to related parties	726	(1,233)	(2,104)	(2,823)
Change in fair value of trading debt securities	107	0	117	0
Other expenses, net	(5)	(3)	(6)	(7)
Total other income (expenses), net	755	(1,261)	(2,161)	(2,823)
Loss from operations before income tax benefit (provision)	(2,266)	(4,120)	(13,443)	(11,015)
Income tax benefit (provision)	(78)	0	1,596	0
Net loss	(2,344)	(4,120)	(11,847)	(11,015)
Less: Net loss attributable to non-controlling interest	(93)	0	(442)	0
Net loss attributable to Catheter Precision, Inc.	$ (2,251)	$ (4,120)	$ (11,405)	$ (11,015)
Net loss per share attributable to Catheter Precision, Inc., basic and diluted (in dollars per share)	$ (1.7)	$ (38.17)	$ (13.02)	$ (176.27)
Weighted-average common shares used in computing net loss per share, basic and diluted (in shares)	1,320,554	107,952	875,627	62,488
Nonrelated Party [Member]
Other income (expenses), net
Interest expense	$ (35)	$ 0	$ (61)	$ (4)
Related Party [Member]
Other income (expenses), net
Interest expense	(48)	(32)	(138)	(36)
Product [Member]
Revenues	$ 226	$ 96	$ 581	$ 271